Cagrilintide
A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese
Novo Nordisk · Phase 1 · Recruiting · Enrollment 100
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Arm 1:Glucose dependent Insulinotropic Polypeptide(GIP)+Cagrilintide then Placebo GIP+Cagrilintide | n/r | n/r | n/r | n/r |
| Arm 2: Placebo GIP + Cagrilintide then GIP + Cagrilintide | n/r | n/r | n/r | n/r |
| Arm 3: GIP + Cagrilintide then Placebo GIP + Cagrilintide | n/r | n/r | n/r | n/r |
| Arm 4: Placebo GIP + Cagrilintide then GIP + Cagrilintide | n/r | n/r | n/r | n/r |
Not shown
- Arm 1:Glucose dependent Insulinotropic Polypeptide(GIP)+Cagrilintide then Placebo GIP+Cagrilintide: endpoint not reported
- Arm 2: Placebo GIP + Cagrilintide then GIP + Cagrilintide: endpoint not reported
- Arm 3: GIP + Cagrilintide then Placebo GIP + Cagrilintide: endpoint not reported
- Arm 4: Placebo GIP + Cagrilintide then GIP + Cagrilintide: endpoint not reported